Lexeo Therapeutics (LXEO) Accumulated Depreciation (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Accumulated Depreciation of $814000.0 for Q1 2026, up 9.85% sequentially from $741000.0 in Q4 2025, and up 52.43% YoY from $534000.0 in Q1 2025.
Lexeo Therapeutics (LXEO) Accumulated Depreciation (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Accumulated Depreciation for 5 years, with the latest figure at $814000.0 in Q1 2026.
- Quarterly Accumulated Depreciation rose 52.43% year-over-year to $814000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $814000.0 (up 52.43% YoY) and the FY2025 annual result came in at $741000.0, up 56.33% from the prior year.
- Accumulated Depreciation improved to $814000.0 in Q1 2026 per LXEO's latest filing, from $741000.0 in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $814000.0 in Q1 2026 and troughed at $133000.0 in Q4 2022.
- A 5-year average of $520333.3 and a median of $530500.0 in 2024 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation jumped 186.47% in 2023, then increased 9.51% in 2025.
- Over 5 years, Accumulated Depreciation stood at $133000.0 in 2022, then surged by 186.47% to $381000.0 in 2023, then gained by 24.41% to $474000.0 in 2024, then soared by 56.33% to $741000.0 in 2025, then gained by 9.85% to $814000.0 in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $814000.0, $741000.0, and $668000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 887,000.00 |
| Mar 31, 2026 | 814,000.00 |
| Dec 31, 2025 | 741,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Jun 30, 2025 | 596,000.00 |
| Mar 31, 2025 | 534,000.00 |
| Dec 31, 2024 | 474,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 527,000.00 |
| Mar 31, 2024 | 450,000.00 |
| Dec 31, 2023 | 381,000.00 |
| Sep 30, 2023 | 316,000.00 |
| Dec 31, 2022 | 133,000.00 |